Eiger appoints Lisa Kelly-Croswell, senior director of human resources and organization, to board of directors

PALO ALTO, Calif., July 18, 2022 /PRNewswire/ — Eiger BioPharmaceuticalsInc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on developing innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious illnesses, today announced the appointment of Lisa Kelly Croswell to its board of directors.

Ms. Kelly-Croswell is an accomplished senior human resources and organizational executive and brings nearly 25 years of experience in the biopharmaceutical and life science industries. She is currently Senior Vice President and Director of Human Resources at Boston Medical Center Health System, where she oversees the organizational program of a $5 billion health system, full-service academic medical center, and 450,000 member managed health care plan.

“Lisa’s extensive experience in biopharma and health systems, as well as her track record of leading significant organizational growth, ideally positions her to bring an important perspective to our Board of Directors,” said Thomas Dietz, PhD, Chairman of the Board, Eiger. “As a seasoned healthcare executive, her insights and perspective will be a valuable addition to our strategic planning process for Eiger’s future organization and late-stage pipeline announcements ahead.”

Prior to her leadership position at Boston Medical Center Health System, Ms. Kelly-Croswell led human resources at Vertex Pharmaceuticals, playing a pivotal role in transforming the company from a research organization into a fully sustainable commercial biotechnology company. . Prior to Vertex, Ms. Kelly-Croswell held positions at Nitromed, Cigna and Monsanto. She currently serves on the Board of Directors of Synlogic and is a current and former board member of several non-profit organizations.

“I am delighted to join Eiger’s Board of Directors at this exciting time in its evolution into a commercial-stage biopharmaceutical company,” said Ms. Kelly-Croswell. “The company’s progress to date has been impressive, and the diverse portfolio of breakthrough treatment programs hold great promise for patients who may ultimately benefit from them. I look forward to being a part of Eiger’s future growth and continued success.

Ms. Kelly-Croswell holds a master’s degree in labor and industrial relations and a bachelor’s degree in finance from the University of Illinois at Urbana-Champaign. She holds the 2022 NEHRA Diversity Champion Award and is the 2021 winner for from boston The most influential black women. She has been featured in the Boston Business Journal and Forbes and is a sought-after speaker and panelist for numerous conferences and organizational events.

About the Eiger

Eiger is a commercial-stage biopharmaceutical company focused on developing innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class Phase 3 therapies that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and has reported positive results from TOGETHER, an investigator-initiated phase 3 study.

Eiger’s five rare disease programs have received FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for congenital hyperinsulinism and post-bariatric hypoglycemia.

For more information about Eiger and its clinical programs, please visit www.eigerbio.com.

contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]

Media:
Sarah Mathieson
SVP, Corporate Affairs
[email protected]

SOURCEEiger BioPharmaceuticals, Inc.

Comments are closed.